Reference Range Study for the Quantra QStat System

July 24, 2020 updated by: HemoSonics LLC
The objective is to determine the reference range intervals for the parameters reported by the Quantra System with the QStat Cartridge.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This is a multicenter, prospective, observational study of a healthy adult population with normal coagulation function to determine the reference range intervals for the parameters reported by the Quantra System with the QStat Cartridge. The threshold for the Clot Stability to Lysis (CSL) parameter will be determined from the CSL reference range.

Study Type

Observational

Enrollment (Actual)

140

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Georgia
      • Sandy Springs, Georgia, United States, 30328
        • WR-Mount Vernon Clinical Research, LLC
    • North Carolina
      • Raleigh, North Carolina, United States, 27612
        • M3 Wake Research
    • Tennessee
      • Chattanooga, Tennessee, United States, 37421
        • WR-Clinsearch, LLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult volunteers with normal coagulation function, approximately equal numbers of males and females across three age group categories (18-30, 31-50 and >50 years). The racial and ethnic profiles will be representative of the populations at each site.

Description

Inclusion Criteria:

  • Subject is 18 years or older
  • Subject is willing to participate and has signed a consent form
  • Subject's laboratory coagulation test results at screening are within each test's normal reference range.

Exclusion Criteria:

  • Subject is younger than 18 years
  • Subject has a history of a coagulation disorder
  • Subject is pregnant or lactating
  • Subject is currently taking medications known to alter coagulation
  • Subject has one or more laboratory coagulation test results outside of the normal reference range at screening
  • Subject had a blood transfusion or surgery within the last month
  • Drug abuse
  • Excessive alcohol consumption
  • Subject is unable to provide written informed consent
  • Subject is incarcerated at the time of the study
  • Subject previously participated in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy volunteers
Blood samples from healthy volunteers analyzed on the Quantra System.
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Other Names:
  • QStat Cartridge

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reference range intervals for measurement of Clot Time (CT) parameter
Time Frame: Baseline, determined from a single blood draw
Reference range intervals determined in this study will serve as the reference range for CT on the QStat Cartridge when it is commercially available.
Baseline, determined from a single blood draw
Reference range intervals for measurement of Clot Stiffness (CS) parameter
Time Frame: Baseline, determined from a single blood draw
Reference range intervals determined in this study will serve as the reference range for CS on the QStat Cartridge when it is commercially available.
Baseline, determined from a single blood draw
Reference range intervals for measurement of Fibrinogen Contribution to Clot Stiffness (FCS) parameter
Time Frame: Baseline, determined from a single blood draw
Reference range intervals determined in this study will serve as the reference range for FCS on the QStat Cartridge when it is commercially available.
Baseline, determined from a single blood draw
Reference range intervals for measurement of Platelet Contribution to Clot Stiffness (PCS) parameter
Time Frame: Baseline, determined from a single blood draw
Reference range intervals determined in this study will serve as the reference range for PCS on the QStat Cartridge when it is commercially available.
Baseline, determined from a single blood draw
Reference range intervals for measurement of Clot Stability to Lysis (CSL) parameter
Time Frame: Baseline, determined from a single blood draw
Reference range intervals determined in this study will serve as the reference range for CSL on the QStat Cartridge when it is commercially available.
Baseline, determined from a single blood draw

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 7, 2020

Primary Completion (Actual)

April 17, 2020

Study Completion (Actual)

June 30, 2020

Study Registration Dates

First Submitted

January 2, 2020

First Submitted That Met QC Criteria

January 3, 2020

First Posted (Actual)

January 7, 2020

Study Record Updates

Last Update Posted (Actual)

July 28, 2020

Last Update Submitted That Met QC Criteria

July 24, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coagulation Disorder

Clinical Trials on Quantra System

Subscribe